S'abonner

The impact of imidacloprid and its metabolites on long-term neurodevelopmental and neurodegenerative disorders in a Zebrafish model - 15/08/22

Doi : 10.1016/j.toxac.2022.06.234 
Megan Mcculloch , Lerato Homu, Carine Smith, Tracy Kellermann
 Clinical pharmacology, Stellenbosch university, Cape Town, South Africa 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Résumé

Aim

This research aimed to assess the impact of lower dose, longer duration exposure of imidacloprid (IMI) on neurodevelopmental and neurodegenerative disorders in comparison to acute exposure within an in vivo zebrafish model. Sensitive, selective, accurate and efficient liquid chromatography tandem mass spectrometry (LC-MS/MS) methods were developed to quantitate bioaccumulation of IMI and its primary metabolites, as well as changes in neurotransmitter concentrations following IMI exposure. This study also assessed liver damage in response to imidacloprid administration as a measure of acute and chronic toxicity in a zebrafish larval model.

Introduction: IMI [1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolidin-2-ylideneamine] is a systemic neonicotinoid insecticide belonging to the chloronicotinyl nitroguanidine chemical family produced to replace the organophosphorus pesticides in commercial agriculture (Crosby EB et al. Neurotoxicol Teratol [Internet]. 2015;49:81–90) (Kumar A et al, Egypt J Forensic Sci [Internet]. 2013;3(4):123–6). The extensive use of these pesticides increases the risk to biodiversity of freshwater aquatic surroundings due to their potential bioaccumulation and toxicity (Muazzam B et al, J Water Supply Res Technol-AQUA. 2019;68(8):718–30). While pesticide usage has economic benefits in large-scale agriculture, exposure can lead to detrimental effects on humans. Researchers studying the effect of IMI on human nicotinic receptors (α4β2) have reported that IMI may have more substantial side effects on humans than originally anticipated (Li P et al, J Neurosci Res. 2011;89(8):1295–301).

Method

Zebrafish larvae were exposed to IMI at 4 and 5 days post fertilisation to determine the no observed adverse effect level (NOAEL) of IMI. Behavioural activity tracking of the zebrafish larvae was monitored using Daniovision software. Oil red O was used to stain for fatty liver accumulation (steatosis) which is indicative of hepatotoxicity following IMI exposure. After this, adult zebrafish were exposed to the NOAEL concentration for 21 days. Key endpoints included developmental effects, behaviour indicative of neuropathology, neurodegeneration and possible bioaccumulation in the adult zebrafish tissues (brain and liver). Neurotransmitter concentrations were measured in the adult zebrafish brain tissue at the end of the treatment period to evaluate changes in neurotransmitter signalling and potential neurodevelopmental effects using a LC-MS/MS method. Bioaccumulation of IMI and its metabolites in zebrafish brain and liver was evaluated using LC-MS/MS.

Results

The NOAEL of IMI in zebrafish larvae was determined to be 2.5μg/L. Hepatotoxicity in the form of steatosis was observed in larvae subsequent to a 5-day treatment period. Adult zebrafish were exposed to the NOAEL IMI concentration for 21 days. No significant behavioural abnormalities were observed in the adult zebrafish during the treatment period. The calibration curve for the neurotransmitters fits a quadratic (weighted 1/C) regression over the concentration range of 3.906–1000ng/mL, 7.813–1000ng/mL, 15.625–1000ng/mL and 31.250–1000ng/mL for acetylcholine, serotonin, gamma-aminobutyric acid and dopamine, respectively. The calibration curve for IMI and its metabolites fits a quadratic (weighted 1/C) regression over the concentration range of 0.098–12.5ng/mL, 0.195–12.5ng/mL, 0.391–12.5ng/mL and 0.781–12.5ng/mL for desnitro-imidacloprid, imidacloprid, imidacloprid-urea and 5-hydro-imidacloprid, respectively.

Conclusion

Robust LC-MS/MS methods were developed for the quantitation of IMI, desnitro-imidacloprid, imidacloprid-urea and 5-hydro-imidacloprid, as well as serotonin, dopamine, acetylcholine and gamma-aminobutyric acid neurotransmitters in 200μl zebrafish brain and liver homogenate. These methods were used to observe changes in neurotransmitter signalling in response to low-level, long-term exposure to imidacloprid, even in the absence of behavioural changes. Furthermore, together with the evaluation of bioaccumulation of imidacloprid and its metabolites in the brain and liver of zebrafish, this study provides indications of impact on human health following chronic neonicotinoid exposure.

Le texte complet de cet article est disponible en PDF.

Plan


© 2022  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 34 - N° 3S

P. S140-S141 - septembre 2022 Retour au numéro
Article précédent Article précédent
  • Occurrence of GHB in blood and urine specimens from victims of alleged sexual assault or blackout in Western Switzerland
  • Caroline Mathon, Aurélien Thomas, Marc Augsburger
| Article suivant Article suivant
  • Automating DUID methods using robotics for rapid high throughput sample preparation – Section 4 and Section 5A UK Road Traffic Act Compounds in Whole Blood
  • Aaron Mcmillan, Mark Evans, Dionne Lawrence, Alongi Talia, Tian Bu, Mark Parkin, Grosse Susan

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.